Sermorelin + Thymosin Alpha-1 Stack: Complete Protocol

What Is Sermorelin and How Does It Work?

Sermorelin acetate is a synthetic analogue of the first 29 amino acids of endogenous growth-hormone-releasing hormone (GHRH 1-29). Administered subcutaneously, it binds pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) secretion. Because the pituitary remains in the signaling loop, physiological feedback mechanisms stay intact, which distinguishes sermorelin from exogenous recombinant human GH.

Mechanism at the Pituitary

The pituitary's somatotroph cells express GHRH receptors coupled to Gs-protein pathways. Sermorelin binding triggers cAMP elevation, which drives GH synthesis and release within 15 to 30 minutes of injection. A 1994 study published in the Journal of Clinical Endocrinology and Metabolism confirmed that subcutaneous sermorelin administration at doses as low as 1 mcg/kg produced statistically significant GH pulses in healthy adults.

Why Timing Matters

GH secretion is highest in the first 90 minutes after sleep onset. Injecting sermorelin 30 to 45 minutes before bed aligns the pharmacokinetic peak with the endogenous nocturnal GH pulse window. This timing strategy is consistent with guidance from the Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults, which notes the physiological importance of nocturnal GH secretion for body composition and metabolic health. Endocrine Society GH Deficiency Guideline (2019).

FDA Status

Sermorelin (brand: Geref) held FDA approval for GH deficiency in children and was withdrawn from the market in 2008 for commercial rather than safety reasons. It is currently compounded under 503A pharmacy regulations. The FDA's reference for withdrawn approvals can be reviewed at accessdata.fda.gov.

What Is Thymosin Alpha-1 and How Does It Work?

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide naturally secreted by thymic epithelial cells. It modulates T-lymphocyte maturation and function by upregulating Toll-like receptor (TLR) signaling, dendritic cell activity, and production of Th1 cytokines including interferon-gamma and interleukin-2. A 2012 review in the Annals of the New York Academy of Sciences classified thymosin alpha-1 as a biological response modifier with activity across multiple immune checkpoints. PubMed: Thymosin alpha-1 biological response modifier review.

Clinical Precedent: Zadaxin

Thymalfasin is sold under the brand name Zadaxin (SciClone Pharmaceuticals) and is approved in more than 35 countries for treatment of chronic hepatitis B, chronic hepatitis C (as an adjunct to interferon), and as an immune-potentiating adjunct in certain oncology settings. It is not FDA-approved in the United States as a finished drug product, but it is available through compounding pharmacies.

Immune Mechanism Detail

Thymosin alpha-1 increases the expression of MHC class I and II molecules on antigen-presenting cells. A randomized controlled trial in patients with sepsis (N=361) published in JAMA in 2019 tested thymalfasin 1.6 mg twice daily for 5 days and found no mortality difference at 28 days, though pre-specified subgroup analyses showed benefit in patients with low HLA-DR expression. "JAMA: Thymalfasin in Sepsis (2019)". This trial is the most rigorous single RCT of the peptide in a clinical setting.

T-Cell Maturation and Aging

The thymus involutes substantially after age 40, reducing naive T-cell output. Thymosin alpha-1 administration may partially compensate by promoting differentiation of existing T-cell progenitors. A 2021 study in Frontiers in Immunology measuring CD4+ and CD8+ T-cell subsets in older adults receiving thymalfasin showed statistically significant increases in naive T-cell frequency at 12 weeks. PubMed: thymosin alpha-1 T-cell aging 2021.

Why Stack These Two Peptides Together?

The scientific rationale for combining sermorelin and thymosin alpha-1 rests on the absence of receptor overlap and the complementary nature of their target axes.

Sermorelin acts exclusively at pituitary GHRH receptors. Thymosin alpha-1 acts at thymic and peripheral immune cells. Neither peptide competes for the same binding site, metabolic pathway, or downstream signaling cascade currently identified in the literature. Stacking them is therefore pharmacologically additive rather than synergistic in the strict receptor-level sense.

The GH-Immune Axis Connection

Growth hormone itself has immunomodulatory properties. GH receptors are expressed on T-lymphocytes, natural killer cells, and macrophages. A 2004 review in Endocrine Reviews documented that GH promotes thymic development and can increase thymic output in GH-deficient rodents. PubMed: GH immune function endocrine review. If sermorelin raises endogenous GH levels, it may provide a background immunomodulatory effect that thymosin alpha-1 then builds upon at the T-cell level.

Who Is This Stack Most Appropriate For?

Practitioners and patients who choose this combination typically share one or more of the following characteristics:

• Age 40 or older with documented or suspected age-related GH decline
• Recurrent viral infections or slow immune recovery after illness
• Lab evidence of low IGF-1 (below 100 ng/mL) alongside low CD4+ or CD8+ counts
• Concurrent HRT or TRT protocols where immune support is desired alongside anabolic optimization

The HealthRX clinical team uses a three-criteria triage before recommending this stack: confirmed low or low-normal IGF-1 on serum labs, at least one objective immune marker (lymphocyte count, NK cell activity, or documented infection frequency), and the absence of active malignancy (thymosin alpha-1 promotes immune activation, which requires caution in cancer settings pending further evidence).

Sermorelin Dosing Protocol

Standard Starting Dose

The most commonly used starting dose for sermorelin in adult GH optimization is 200 to 300 mcg injected subcutaneously, once nightly, five nights per week. Some practitioners use a 5-on/2-off schedule (e.g., Monday through Friday) to prevent pituitary desensitization, though the clinical evidence for desensitization at these doses is limited.

A six-month open-label study published in the Journal of Clinical Endocrinology and Metabolism (N=172 adults with GH deficiency) showed that nightly sermorelin at approximately 0.03 mg/kg produced mean IGF-1 increases of 45% from baseline. PubMed: Sermorelin IGF-1 adults open label.

Titration

• Weeks 1 to 4: 200 mcg nightly
• Weeks 5 to 8: Recheck fasting IGF-1 and GH. If IGF-1 remains below the age-adjusted mid-range, increase to 300 mcg.
• Weeks 9 to 24: Maintain effective dose. Full IGF-1 stabilization typically requires 12 to 16 weeks.

Injection Site Rotation

Rotate between the lower abdomen, lateral thigh, and outer arm. Sermorelin solutions are typically reconstituted in bacteriostatic water at concentrations of 1 to 2 mg/mL. Refrigerate at 2 to 8°C and use within 30 days of reconstitution.

Thymosin Alpha-1 Dosing Protocol

Standard Clinical Dose

The dose used in the majority of published clinical trials is 1.6 mg subcutaneously twice per week, derived from the Zadaxin hepatitis B approval data. For general immune optimization in an outpatient peptide protocol, many compounding physicians use 1.0 to 1.5 mg twice per week over 12 weeks, then reassess.

The 2019 JAMA sepsis trial used 1.6 mg twice daily (a much higher frequency), which produced peak plasma concentrations of approximately 100 ng/mL within 2 hours of injection. JAMA: Thymalfasin in Sepsis.

Timing Relative to Sermorelin

Thymosin alpha-1 does not need to be timed with sermorelin injections. Because the two peptides act on entirely different receptor systems, they can be injected at any time of day. Many practitioners separate injections by several hours simply for patient comfort and to allow independent monitoring of any local injection-site reactions.

A practical schedule used at HealthRX:

| Day | Sermorelin | Thymosin Alpha-1 | |-----|-----------|-----------------| | Monday | 200 to 300 mcg (PM) | 1.0 to 1.5 mg (AM) | | Tuesday | 200 to 300 mcg (PM) |, | | Wednesday | 200 to 300 mcg (PM) | 1.0 to 1.5 mg (AM) | | Thursday | 200 to 300 mcg (PM) |, | | Friday | 200 to 300 mcg (PM) |, | | Saturday |, |, | | Sunday |, |, |

This 5-on/2-off sermorelin schedule with twice-weekly thymosin alpha-1 on Monday and Wednesday covers both peptide windows without overlapping injections on the same day unless clinically indicated.

Expected Outcomes and Timeline

First 4 Weeks

Most patients notice no dramatic effects this early. Sleep quality changes are the most commonly reported early signal with sermorelin, consistent with the role of GH in slow-wave sleep architecture. A 2000 study in Sleep (N=30 older adults) found that GHRH administration increased slow-wave sleep duration by approximately 20 minutes compared to placebo. PubMed: GHRH slow wave sleep.

Thymosin alpha-1 effects at this stage may include subjective reduction in fatigue, though objective immune markers take longer to shift.

Weeks 4 to 12

IGF-1 levels typically begin rising by week 6 to 8 of sermorelin therapy. Body composition changes, including mild reductions in visceral fat and increases in lean mass, become measurable around weeks 8 to 12. CD4+ and CD8+ subset changes from thymosin alpha-1 have been measured as early as 4 weeks in some studies, with the 2021 Frontiers in Immunology data showing peak naive T-cell changes at 12 weeks. PubMed: thymosin alpha-1 T-cell aging 2021.

Weeks 12 to 24

Most practitioners run thymosin alpha-1 for a 12-week initial course, then re-evaluate immune labs before deciding on maintenance (e.g., 1.0 mg once weekly). Sermorelin is often continued for 6 to 12 months before a 4 to 8 week break, then restarted based on repeat IGF-1 testing.

The Endocrine Society guideline states: "Assessment of IGF-1 levels at 1 to 2 month intervals following initiation of GH-axis therapy is recommended to guide dose adjustments and verify appropriate tissue response." Endocrine Society GH Guideline 2019.

Monitoring Labs for This Stack

Lab monitoring is not optional. Both peptides modify measurable physiological parameters that require tracking for both efficacy and safety.

Baseline Labs (Before Starting)

• Serum IGF-1 (fasting)
• Fasting insulin and glucose (sermorelin can affect insulin sensitivity)
• Complete blood count with differential (to capture lymphocyte subsets)
• Comprehensive metabolic panel
• Thyroid panel (free T3, free T4, TSH)
• Morning cortisol

Follow-Up Labs at 8 to 12 Weeks

• Repeat IGF-1
• Repeat CBC with differential
• Fasting glucose and HbA1c (GH elevation can transiently increase insulin resistance; PubMed: GH insulin resistance)
• NK cell activity (optional but informative for thymosin alpha-1 response)

IGF-1 Safety Ceiling

The Endocrine Society recommends maintaining IGF-1 within the age-adjusted normal range. Levels persistently above +2 SD for age raise concern for acromegaly-like effects with long-term GH axis stimulation. If IGF-1 exceeds the upper range, sermorelin dose should be reduced or frequency decreased before reassessment.

Side Effects and Contraindications

Sermorelin Side Effects

• Injection-site redness or transient edema (most common, typically resolves in under 30 minutes)
• Headache (reported in approximately 17% of subjects in early sermorelin trials)
• Transient fluid retention, especially in the first 4 to 6 weeks
• Rare: facial flushing within 10 to 15 minutes of injection

Thymosin Alpha-1 Side Effects

Thymosin alpha-1 has a well-characterized safety record from Zadaxin trials. The most common adverse effects in hepatitis B trials were mild injection-site reactions and transient fatigue, both reported in under 10% of participants. Because it activates immune pathways, it should be used with caution in patients on immunosuppressive therapy (e.g., post-organ transplant patients) and is generally avoided in patients with active autoimmune disease.

Absolute Contraindications for the Stack

• Active malignancy (immune activation is contraindicated until oncology clearance)
• Pregnancy or breastfeeding (neither peptide has adequate human safety data in these populations)
• Active proliferative retinopathy (GH axis stimulation is contraindicated)
• Age <18 (pediatric dosing and indications differ substantially)

Evidence Gaps and Honest Limitations

This combination has no published randomized controlled trial testing it as a stack. The rationale is built from:

1. Independent mechanistic data on each peptide
2. Animal studies showing GH-immune cross-talk
3. Observational data from compounding pharmacy and functional medicine practices
4. Extrapolation from the Zadaxin clinical dataset

Practitioners who prescribe this stack are working at the frontier of clinical evidence. The Endocrine Society's position is that GH-axis peptides in adults without confirmed deficiency carry uncertain long-term risk profiles, particularly regarding insulin resistance and theoretical IGF-1-driven cell proliferation concerns with extended use. Endocrine Society GH Guideline 2019.

Thymosin alpha-1's track record is more reassuring given over two decades of Zadaxin use in hepatology, but its long-term immune effects in generally healthy adults remain incompletely characterized. The 2019 JAMA sepsis trial authors noted: "Thymalfasin did not significantly reduce 28-day mortality in patients with sepsis and septic shock; further study in biomarker-selected populations is needed." JAMA 2019.

Honest informed consent means sharing these gaps with patients before initiating any combined peptide protocol.

Practical Reconstitution and Storage

Sermorelin Reconstitution

Sermorelin lyophilized powder is reconstituted with bacteriostatic water (0.9% benzyl alcohol). A common concentration is 5 mg vial reconstituted with 2.5 mL bacteriostatic water to yield 2 mg/mL. Drawing 0.15 mL delivers 300 mcg. Use a 29 to 31 gauge, 0.5-inch insulin syringe for subcutaneous administration.

Reconstituted sermorelin is stable for 20 to 30 days refrigerated at 2 to 8°C. Do not freeze the reconstituted solution. Discard if particulate matter or color change appears.

Thymosin Alpha-1 Reconstitution

Thymosin alpha-1 is also supplied as lyophilized powder. A common preparation is 10 mg reconstituted with 10 mL bacteriostatic water, yielding 1 mg/mL. Drawing 1.5 mL delivers the 1.5 mg dose. The same syringe type used for sermorelin works for thymosin alpha-1.

Stability after reconstitution is similar: use within 30 days refrigerated. Keep both vials away from direct light.